A Gene Panel Associated With Abemaciclib Utility in <i>ESR1</i>-Mutated Breast Cancer After Prior Cyclin-Dependent Kinase 4/6-Inhibitor Progression
Jamie O. Brett(Harvard University), Seth A. Wander(Harvard University), Siobhan Dunne(Texas Oncology), Azadeh Nasrazadani(The University of Texas MD Anderson Cancer Center), Beverly Moy(Global Cancer Institute), Laura M. Spring(Massachusetts General Hospital), Andrzej Niemierko(Harvard University), Taronish D. Dubash(Harvard University), Aditya Bardia(UCLA Health), X. Cynthia(Washington University in St. Louis), Daniel A. Haber(Howard Hughes Medical Institute), Avinash Kambadakone(Harvard University), Lianne Ryan(Harvard University), Adam Brufsky(University of Pittsburgh), Utthara Nayar, Leslie S.L. Kim(Texas Oncology), Dante Che(Harvard University), Leif W. Ellisen(Harvard University), Veronica Mariotti(Moffitt Cancer Center), Kevin Kalinsky(Emory University), Gabriela N. Johnson(Harvard University), A. John Iafrate(Massachusetts General Hospital), Hyo S. Han(Moffitt Cancer Center), Maxwell R. Lloyd(Beth Israel Deaconess Medical Center), Nikhil Wagle(Dana-Farber Cancer Institute), Shyamala Maheswaran(Massachusetts General Hospital), Joyce O’Shaughnessy(Baylor University Medical Center), Dejan Juric(Massachusetts General Hospital), Maristela L. Onozato(Harvard University), Douglas S. Micalizzi(Massachusetts General Hospital), Jing Xi(Washington University in St. Louis), Apurva Pandey(University of Pittsburgh Medical Center)
Cited by 16